Do you want to read an article? Please log in or register.
Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Fecal Microbiota Transplantation Outcome and Gut Microbiota Composition in Ulcerative Colitis: a Systematic Review and Meta-analysis
Clin Gastroenterol Hepatol
Bénard MV, de Goffau MC, Blonk J, Hugenholtz F, van Buuren J, Paramsothy S, Kaakoush NO, D'Haens GRAM, Borody TJ, Kamm MA, Ponsioen CY
doi: 10.1016/j.cgh.2024.10.001
RECOMMENDED
Inflammatory Bowel Disease
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Inflamm Bowel Dis
Lopetuso LR, Deleu S, Puca P, Abreu MT, Armuzzi A, Barbara G, Caprioli F, Chieng S, Costello SP, Damiani A, Danese S, Del Chierico F, D'Haens G, Dotan I, Facciotti F, Falony G, Fantini MC, Fiorino G, Gionchetti P, Godny L, Hart A, Kupčinskas J, Iqbal T, Laterza L, Lombardini L, Maharshak N, Marasco G, Masucci L, Papa A, Paramsothy S, Petito V, Piovani D, Pugliese D, Putignani L, Raes J, Ribaldone DG, Sanguinetti M, Savarino EV, Sokol H, Vetrano S, Ianiro G, Cammarota G, Cominelli F, Pizarro TT, Tilg H, Gasbarrini A, Vermeire S, Scaldaferri F
doi: 10.1093/ibd/izaf013
RECOMMENDED
Inflammatory Bowel Disease
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
ACCURE Study Group
doi: 10.1016/S2468-1253(25)00026-3
Inflammatory Bowel Disease
Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Systemic Review and Network Meta-analysis
J Crohns Colitis
Huang CW, Yen HH, Chen YY
doi: 10.1093/ecco-jcc/jjae111
Gastrointestinal Cancer
The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy
J Crohns Colitis
Visser E, Luberto A, Heuthorst L, Hompes R, Vermeire S, D'Haens GR, Bemelman WA, D'Hoore A, Bislenghi G, Buskens CJ
doi: 10.1093/ecco-jcc/jjaf015
Inflammatory Bowel Disease
Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis
Inflamm Bowel Dis
Shehab M, Hassan A, Alrashed F, Abbas A, Ma C, Narula N, Jairath V, Singh S, Bessissow T
doi: 10.1093/ibd/izae163
Inflammatory Bowel Disease
Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis
Inflamm Intest Dis
Grob F, Häberling I, Novacek G, Kreienbühl A, Biedermann L, Rogler G, Schreiner P
doi: 10.1159/000546511
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P
doi: 10.1016/S2468-1253(24)00200-0